Interactions between cyclosporin and lipid-lowering drugs: Implications for organ transplant recipients

Drugs

Volumn 63, Issue 4, 2003, Pages 367-378

  Åsberg, Anders ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID; CERIVASTATIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TETRAHYDROLIPSTATIN;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EXPOSURE; DRUG INHIBITION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; ORGAN TRANSPLANTATION; POPULATION; PROBABILITY; RECIPIENT; REDUCTION; REGULATORY MECHANISM; REVIEW; THEORETICAL MODEL;

ACIDS, ACYCLIC; ANTILIPEMIC AGENTS; AREA UNDER CURVE; BILE ACIDS AND SALTS; CLINICAL TRIALS; CYCLOSPORINE; DRUG INTERACTIONS; FISH OILS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; LACTONES; ORGAN TRANSPLANTATION; PROBUCOL; QUATERNARY AMMONIUM COMPOUNDS;

EID: 0037287596     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363040-00003     Document Type: Review

References (71)

1. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57 (1): 307-13
2. Wierzbicki AS. The role of lipid lowering in transplantation. Int J Clin Pract 1999; 53 (1): 54-9
3. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35 (9): 1096-107
4. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36 (2): 288-95
5. Jardine A. Assessing cardiovascular risk profile of immunosuppressive agents. Transplantation 2001; 72 (12 Suppl.): S81-S8
6. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80 (1): 1-34
7. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25 (10): 1191-9
8. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998; 55 (21): 2253-67
9. Mück W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998; 56 Suppl. 1: 15-23
10. Jacobsen W, Kirchner G, Hallensleben K, et al. Comparison of cytochrome P-450-dependent metabolism and drug interac tions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27 (2): 173-9
11. Jacobsen W, Kirchner G, Hallensleben K, et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 1999; 291 (1): 131-9
12. Singhvi SM, Pan HY, Morrison RA, et al. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29 (2): 239-43
13. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27 (3): 410-6
14. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40 (4): 263-81
15. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40 (3): 159-68
16. Bramow S, Ott P, Thomsen Nielsen F, et al. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001; 89 (3): 133-9
17. Akhlaghi F, McLachlan AJ, Keogh AM, et al. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997; 44 (6): 537-42
18. Garcia-Saiz M, Lopez-Gil A, Alfonso I, et al. Factors influencing cyclosporine blood concentration-dose ratio. Ann Pharmacother 2002; 36 (2): 193-9
19. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62 (3): 311-21
20. Gullestad L, Nordal KP, Berg KJ, et al. Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc 1999; 31 (5): 2163-5
21. Traindl O, Reading S, Franz M, et al. Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A. Transplant Proc 1992; 24 (6): 2745-7
22. Arnadottir M, Eriksson LO, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65 (3): 410-3
23. Arnadottir M, Eriksson LO, Germershausen JI, et al. Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994; 68 (1): 57-62
24. Campana C, lacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29 (3): 235-9
25. Rehman MA, al-Sulaiman MH, Mousa DH, et al. Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine. Transplantation 1995; 60 (4): 397-9
26. Martinez Hernandez BE, Persaud JW, Varghese Z, et al. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993; 8 (7): 637-41
27. Capone D, Stanziale P, Gentile A, et al. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. Am J Nephrol 1999; 19 (3): 411-5
28. Pflugfelder PW, Huff M, Oskalns R, et al. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995; 14 (4): 613-22
29. Vanhaecke J, Van Cleemput J, Van Lierde J, et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58 (1): 42-5
30. Lepre F, Rigby R, Hawley C, et al. A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. Clin Transplant 1999; 13 (6): 520-5
31. Castelao AM, Grinyo JM, Castineiras MJ, et al. Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc 1995; 27 (4): 2217-20
32. Regazzi MB, Iacona I, Campana C, et al. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994; 26 (5): 2644-5
33. Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int J Clin Pharmacol Ther 2002; 10 (10): 439-50
34. Schrama YC, Hene RJ, de Jonge N, et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test. Transplantation 1998; 66 (9): 1175-81
35. Holdaas H, Hartmann A, Stenstrøm J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76 (2): 102A-6A
36. Martínez-Castelao A, Grinyo JM, Fiol C, et al. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients. Kidney Int Suppl 1999; 71: S231-4
37. Li PK, Mak TW, Wang AY, et al. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther 1995; 33 (4): 246-8
38. Hadjigavriel M, Kyriakides G. Fluvastatin in renal transplantation. Transplant Proc 1997; 29 (7): 3050
39. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62 (11): 1559-64
40. Park JW, Siekmeier R, Lattke P, et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 2001; 6 (4): 351-61
41. Demetriou D, Shabpar A, Bohmig G, et al. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation. Wien Klin Wochenschr 2000; 112 (8): 358-61
42. Renders L, Mayer-Kadner I, Koch C, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001; 16: 141-6
43. Åsberg A, Hartmann A, Fjeldså E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001; 1 (4): 382-6
44. Mück W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65 (3): 251-61
45. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257 (3): 1225-35
46. Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132 (6): 1183-92
47. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40 (1): 91-8
48. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274 (52): 37161-8
49. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17 (2): 209-15
50. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34 (2): 155-62
51. Pisanti N, Stanziale P, Imperatore P, et al. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. Am J Nephrol 1998; 18 (3): 199-203
52. Fehrman-Ekholm I, Jogestrand T, Angelin B. Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation. Nephron 1996; 72 (3): 483
53. Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58 (2): 245-7
54. deLorgeril M, Boissonnat P, Bizollon CA, et al. Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation: lack of interaction with the lipid-lowering agent, fenofibrate. Eur J Clin Pharmacol 1992; 43 (2): 161-5
55. Jensen RA, Lal SM, Diaz-Arias A, et al. Does cholestyramine interfere with cyclosporine absorption? A prospective study in renal transplant patients. ASAIO J 1995; 41 (3): M704-6
56. Keogh A, Day R, Critchley L, et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20 (1): 27-30
57. Gallego C, Sanchez P, Planells C, et al. Interaction between probucol and cyclosporine in renal transplant patients. Ann Pharmacother 1994; 28 (7-8): 940-3
58. Wakasugi H, Yoshimoto M, Aoki M, et al. Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome. Nippon Jinzo Gakkai Shi 2001; 43 (7): 595-9
59. Sugimoto K, Sakamoto K, Fujimura A. Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats. Life Sci 1997; 60 (3): 173-9
60. Bays HE, Dujovne CA. Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Prog Drug Res 1994; 43: 9-41
61. Homan van der Heide JJ, Bilo HJ, Donker JM, et al. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993; 329 (11): 769-73
62. Homan van der Heide JJ, Bilo HJ, Donker AJ, et al. Dietary supplementation with fish oil modifies renal reserve filtration capacity in postoperative, cyclosporin A-treated renal transplant recipients. Transpl Int 1990; 3 (3): 171-5
63. Homan van der Heide JJ, Bilo HJ, Donker AJ, et al. The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients. Transplantation 1992; 54 (2): 257-63
64. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994; 58 (6): 658-63
65. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25 (11): 1713-21
66. Nägele H, Petersen B, Bonacker U, et al. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. Eur J Clin Pharmacol 1999; 55 (9): 667-9
67. le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000; 70 (10): 1541-2
68. Schnetzler B, Kondo-Oestreicher M, Vala D, et al. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation 2000; 70 ( 10): 1540-1
69. Errasti P, Garcia I, Lavilla J, et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc 2002; 34 (1): 137
70. Barbaro D, Orsini P, Pallini S, et al. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002; 8 (2): 124
71. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002; 42 (9): 1011